BNTX logo

BioNTech SE (BNTX) Cash from operations

annual CFO:

$224.67M-$5.58B(-96.13%)
December 31, 2024

Summary

  • As of today (August 18, 2025), BNTX annual cash flow from operations is $224.67 million, with the most recent change of -$5.58 billion (-96.13%) on December 31, 2024.
  • During the last 3 years, BNTX annual CFO has fallen by -$826.94 million (-78.64%).
  • BNTX annual CFO is now -98.43% below its all-time high of $14.27 billion, reached on December 31, 2022.

Performance

BNTX Cash from operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBNTXcash flow metrics

quarterly CFO:

$132.14M+$953.79M(+116.08%)
June 30, 2025

Summary

  • As of today (August 18, 2025), BNTX quarterly cash flow from operations is $132.14 million, with the most recent change of +$953.79 million (+116.08%) on June 30, 2025.
  • Over the past year, BNTX quarterly CFO has dropped by -$1.63 billion (-92.49%).
  • BNTX quarterly CFO is now -97.27% below its all-time high of $4.84 billion, reached on September 30, 2022.

Performance

BNTX quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBNTXcash flow metrics

TTM CFO:

-$1.88B-$1.63B(-647.24%)
June 30, 2025

Summary

  • As of today (August 18, 2025), BNTX TTM cash flow from operations is -$1.88 billion, with the most recent change of -$1.63 billion (-647.24%) on June 30, 2025.
  • Over the past year, BNTX TTM CFO has dropped by -$5.04 billion (-159.37%).
  • BNTX TTM CFO is now -113.27% below its all-time high of $14.16 billion, reached on December 31, 2022.

Performance

BNTX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBNTXcash flow metrics

Cash from operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

BNTX Cash from operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-96.1%-92.5%-159.4%
3 y3 years-78.6%-96.8%-118.3%
5 y5 years+201.1%+888.4%-825.6%

BNTX Cash from operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-98.4%at low-97.3%+116.1%-113.3%at low
5 y5-year-98.4%+201.1%-97.3%+116.1%-113.3%at low
alltimeall time-98.4%+201.1%-97.3%+116.1%-113.3%at low

BNTX Cash from operations History

DateAnnualQuarterlyTTM
Jun 2025
-
$132.14M(-116.1%)
-$1.88B(+647.2%)
Mar 2025
-
-$821.66M(+63.9%)
-$251.40M(-211.3%)
Dec 2024
$224.67M(-96.1%)
-$501.21M(-27.1%)
$225.87M(-85.7%)
Sep 2024
-
-$687.85M(-139.1%)
$1.58B(-50.1%)
Jun 2024
-
$1.76B(-610.9%)
$3.16B(-48.6%)
Mar 2024
-
-$344.38M(-140.5%)
$6.15B(+6.6%)
Dec 2023
$5.81B(-59.3%)
$850.76M(-5.3%)
$5.77B(+4.8%)
Sep 2023
-
$898.37M(-81.1%)
$5.51B(-41.7%)
Jun 2023
-
$4.75B(-753.0%)
$9.45B(+6.3%)
Mar 2023
-
-$726.81M(-223.5%)
$8.89B(-37.2%)
Dec 2022
$14.27B(+1256.9%)
$588.71M(-87.8%)
$14.16B(+6.3%)
Sep 2022
-
$4.84B(+15.7%)
$13.32B(+29.6%)
Jun 2022
-
$4.19B(-7.9%)
$10.28B(+72.1%)
Mar 2022
-
$4.54B(-1908.1%)
$5.97B(+467.2%)
DateAnnualQuarterlyTTM
Dec 2021
$1.05B(-6946.4%)
-$251.29M(-114.0%)
$1.05B(-33.5%)
Sep 2021
-
$1.80B(-1590.9%)
$1.58B(-464.5%)
Jun 2021
-
-$120.71M(-67.8%)
-$434.09M(+31.5%)
Mar 2021
-
-$374.96M(-234.8%)
-$330.14M(+2040.0%)
Dec 2020
-$15.36M(-93.1%)
$278.19M(-228.4%)
-$15.43M(-95.8%)
Sep 2020
-
-$216.61M(+1192.5%)
-$365.82M(+80.2%)
Jun 2020
-
-$16.76M(-72.2%)
-$202.96M(-17.8%)
Mar 2020
-
-$60.25M(-16.6%)
-$247.01M(+11.2%)
Dec 2019
-$222.21M(+223.7%)
-$72.21M(+34.4%)
-$222.22M(+48.1%)
Sep 2019
-
-$53.75M(-11.6%)
-$150.01M(+55.8%)
Jun 2019
-
-$60.80M(+71.5%)
-$96.26M(+171.5%)
Mar 2019
-
-$35.46M
-$35.46M
Dec 2018
-$68.64M(+15.8%)
-
-
Dec 2017
-$59.29M
-
-

FAQ

  • What is BioNTech SE annual cash flow from operations?
  • What is the all time high annual CFO for BioNTech SE?
  • What is BioNTech SE annual CFO year-on-year change?
  • What is BioNTech SE quarterly cash flow from operations?
  • What is the all time high quarterly CFO for BioNTech SE?
  • What is BioNTech SE quarterly CFO year-on-year change?
  • What is BioNTech SE TTM cash flow from operations?
  • What is the all time high TTM CFO for BioNTech SE?
  • What is BioNTech SE TTM CFO year-on-year change?

What is BioNTech SE annual cash flow from operations?

The current annual CFO of BNTX is $224.67M

What is the all time high annual CFO for BioNTech SE?

BioNTech SE all-time high annual cash flow from operations is $14.27B

What is BioNTech SE annual CFO year-on-year change?

Over the past year, BNTX annual cash flow from operations has changed by -$5.58B (-96.13%)

What is BioNTech SE quarterly cash flow from operations?

The current quarterly CFO of BNTX is $132.14M

What is the all time high quarterly CFO for BioNTech SE?

BioNTech SE all-time high quarterly cash flow from operations is $4.84B

What is BioNTech SE quarterly CFO year-on-year change?

Over the past year, BNTX quarterly cash flow from operations has changed by -$1.63B (-92.49%)

What is BioNTech SE TTM cash flow from operations?

The current TTM CFO of BNTX is -$1.88B

What is the all time high TTM CFO for BioNTech SE?

BioNTech SE all-time high TTM cash flow from operations is $14.16B

What is BioNTech SE TTM CFO year-on-year change?

Over the past year, BNTX TTM cash flow from operations has changed by -$5.04B (-159.37%)
On this page